U.S. markets open in 5 hours 3 minutes

Catalent, Inc. (CTLT)

NYSE - NYSE Precio retrasado. Divisa en USD.
Añadir a la lista de seguimiento
53.55+0.97 (+1.84%)
Al cierre: 04:04PM EST
54.80 +1.25 (+2.33%)
Fuera de horario: 07:41PM EST

Catalent, Inc.

14 Schoolhouse Road
Somerset, NJ 08873
United States
732 537 6200
https://www.catalent.com

Sector(es)Healthcare
IndustriaDrug Manufacturers—Specialty & Generic
Empleados a tiempo completo19,000

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. John R. ChiminskiExec. Chair of the Board3.11M6.94M1964
Mr. Alessandro MaselliCEO & Director1.53MN/D1972
Mr. Thomas P. CastellanoSr. VP & CFO1.07MN/D1980
Mr. Steven L. Fasman Esq.Exec. VP, Corp. Sec. & Chief Admin. Officer1.3M1.34M1963
Dr. Aristippos Gennadios Ph.D.Group Pres of Pharma & Consumer Health Segment1.13MN/D1966
Mr. Ricky HopsonPres & Division Head for Clinical Devel. and SupplyN/DN/D1976
Ms. Karen Murphy SantiagoVP & Chief Accounting OfficeN/DN/D1971
Mr. Julien MeissonnierVP & Chief Scientific OfficerN/DN/DN/D
Mr. Charles LickfoldSr. VP & Chief Information OfficerN/DN/D1974
Mr. Paul SurdezVP of Investor RelationsN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Gestión corporativa

La calificación ISS Governance QuickScore de Catalent, Inc. a partir del 28 de enero de 2023 es 7. Las puntuaciones principales son Auditoría: 6; Junta: 8; Derechos del accionista: 6; Compensación: 7.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.